Kitago Minoru, Martinez Steve R, Nakamura Takeshi, Sim Myung-Shin, Hoon Dave S B
Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, USA.
Clin Cancer Res. 2009 May 1;15(9):2988-94. doi: 10.1158/1078-0432.CCR-08-3172. Epub 2009 Mar 31.
RUNX3 is a known tumor suppressor gene in several carcinomas. Aberration in RUNX3 expression has not been described for cutaneous melanoma. Therefore, we assessed the expression of RUNX3 in cutaneous melanoma and its regulatory mechanisms relative to tumor progression.
The expression of RUNX3 mRNA and miR-532-5p (microRNA) was assessed in melanoma lines and in primary and metastatic melanoma tumors.
RUNX3 mRNA expression was down-regulated in 11 of 11 (100%) metastatic melanoma lines relative to normal melanocytes (P < 0.001). Among 123 primary and metastatic melanoma tumors and 12 normal skin samples, RUNX3 expression was significantly down-regulated in primary melanomas (n = 82; P = 0.02) and in melanoma metastasis (n = 41; P < 0.0001) versus normal skin (n = 12). This suggested that RUNX3 down-regulation may play a role in the development and progression of melanoma. RUNX3 promoter region hypermethylation was assessed as a possible regulator of RUNX3 expression using methylation-specific PCR. Assessment of RUNX3 promoter region methylation showed that only 5 of 17 (29%) melanoma lines, 2 of 52 (4%) primary melanomas, and 5 of 30 (17%) metastatic melanomas had hypermethylation of the promoter region. A microRNA (miR-532-5p) was identified as a target of RUNX3 mRNA sequences. miR-532-5p expression was shown to be significantly up-regulated in melanoma lines and metastatic melanoma tumors relative to normal melanocytes and primary melanomas, respectively. To investigate the relation between RUNX3 and miR-532-5p, anti-miR-532-5p was transfected into melanoma lines. Inhibition of miR-532-5p up-regulated both RUNX3 mRNA and protein expression.
RUNX3 is down-regulated during melanoma progression and miR-532-5p is a regulatory factor of RUNX3 expression.
RUNX3是几种癌症中已知的肿瘤抑制基因。皮肤黑色素瘤中尚未描述RUNX3表达的异常情况。因此,我们评估了RUNX3在皮肤黑色素瘤中的表达及其与肿瘤进展相关的调控机制。
在黑色素瘤细胞系以及原发性和转移性黑色素瘤肿瘤中评估RUNX3 mRNA和miR-532-5p(微小RNA)的表达。
相对于正常黑素细胞,11个转移性黑色素瘤细胞系中的11个(100%)RUNX3 mRNA表达下调(P < 0.001)。在123个原发性和转移性黑色素瘤肿瘤以及12个正常皮肤样本中,与正常皮肤(n = 12)相比,原发性黑色素瘤(n = 82;P = 0.02)和黑色素瘤转移灶(n = 41;P < 0.0001)中RUNX3表达均显著下调。这表明RUNX3下调可能在黑色素瘤的发生和发展中起作用。使用甲基化特异性PCR评估RUNX3启动子区域高甲基化作为RUNX3表达的可能调节因子。RUNX3启动子区域甲基化评估显示,仅17个黑色素瘤细胞系中的5个(29%)、52个原发性黑色素瘤中的2个(4%)和30个转移性黑色素瘤中的5个(17%)存在启动子区域高甲基化。一种微小RNA(miR-532-5p)被鉴定为RUNX3 mRNA序列的靶点。相对于正常黑素细胞和原发性黑色素瘤,miR-532-5p表达分别在黑色素瘤细胞系和转移性黑色素瘤肿瘤中显著上调。为了研究RUNX3与miR-532-5p之间的关系,将抗miR-532-5p转染到黑色素瘤细胞系中。抑制miR-532-5p可上调RUNX3 mRNA和蛋白表达。
在黑色素瘤进展过程中RUNX3表达下调,miR-532-5p是RUNX3表达的调节因子。